BCR and TLR signalling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.

Détails

Ressource 1Télécharger: 22102703.pdf (401.33 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_2768CC12F804
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
BCR and TLR signalling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.
Périodique
Haematologica
Auteur⸱e⸱s
Yan Y., Huang Y., Watkins A.J., Kocialkowski S., Zeng N., Hamoudi R.A., Isaacson P.G., de Leval L., Wotherspoon A., Du M.Q.
ISSN
0390-6078
ISSN-L
1592-8721
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Pages
-
Langue
anglais
Résumé
The genetics and pathogenesis of splenic marginal zone lymphoma are poorly understood. The lymphoma lacks chromosome translocation, and ~30% of cases are featured by 7q deletion, but the gene targeted by the deletion is unknown. A recent study showed inactivation of A20, a 'global' NF-kB negative regulator, in 1 of 12 splenic marginal zone lymphoma. To investigate further whether deregulation of the NF-kB pathway plays a role in the pathogenesis of splenic marginal zone lymphoma, we screened several NF-kB regulators for genetic changes by PCR and sequencing. Somatic mutations were found in A20 (6/46=13%), MYD88 (6/46=13%), CARD11 (3/34=8.8%), but not in CD79A, CD79B and ABIN1. Interestingly, these genetic changes are largely mutually exclusive from each other and MYD88 mutation was also mutually exclusive from 7q deletion. These results strongly suggest that deregulation of the TLR (toll like receptor) and BCR (B-cell receptor) signalling pathway may play an important role in the pathogenesis of splenic marginal zone lymphoma.
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/02/2012 11:04
Dernière modification de la notice
20/08/2019 14:06
Données d'usage